The AABB Annual Meeting allowed subject matter experts from various organizations to share their latest work and practice-changing resources for the fields of blood and biotherapies. Representatives from several of New York Blood Center Enterprises’ (NYBCe) divisions submitted their late-breaking abstracts to the conference. Others participated in continuing education sessions. You can download the 2020 schedule for Oral Abstract Presentations and Continuing Education Sessions here.
NYBCe’s research is not limited to what is presented at AABB, however. Our divisions continue to pave the way for new blood-related products, techniques and therapies year-round.
In 2019, our team focused on advancing our understanding of COVID-19 through the COVID-19 Research Repository. Through this initiative, NYBCe initiated pre-clinical phase trials for multiple SARS-CoV-2 vaccine and adjuvant candidates as well as screened plasma for novel biomarkers to predict COVID-19 responses in patients and help accelerate the recovery of the nation.
Over the years, our subject matter experts have also published helpful resources on cellular therapies, genomics, and more.
Click on the links below to download additional work from NYBCe representatives and learn more about the ground-breaking research conducted by our organization.
- “The Adjuvanticity of an O. volvulus-Derived rOv-ASP-1 Protein in Mice Using Sequential Non-Human Primates” by Wang et al. (2020)
- “Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses” by Jiang et al. (2020)
- “Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients” by Luchsinger et al. (2020)
- “Validation of simple prediction algorithms to consistently achieve CD3+ and postselection CD34+ targets with leukapheresis” by Yoon et al. (2019)
- “Common Questions About: Cellular Starting Material, Cell-Based Therapies & Induced Pluripotent Stem Cells (iPSCs)” by Comprehensive Cell Solutions (2019)
- “It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype” by Sandler et al. (2015)